ST Germain D J Co. Inc. Sells 937 Shares of Johnson & Johnson (NYSE:JNJ)

ST Germain D J Co. Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 155,676 shares of the company’s stock after selling 937 shares during the quarter. Johnson & Johnson comprises about 1.0% of ST Germain D J Co. Inc.’s portfolio, making the stock its 21st biggest position. ST Germain D J Co. Inc.’s holdings in Johnson & Johnson were worth $22,514,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Legacy Private Trust Co. raised its stake in Johnson & Johnson by 8.4% in the fourth quarter. Legacy Private Trust Co. now owns 39,173 shares of the company’s stock worth $5,665,000 after buying an additional 3,047 shares in the last quarter. Douglas Lane & Associates LLC lifted its stake in shares of Johnson & Johnson by 1.1% during the 4th quarter. Douglas Lane & Associates LLC now owns 599,386 shares of the company’s stock worth $86,683,000 after purchasing an additional 6,526 shares during the last quarter. InvesTrust purchased a new position in Johnson & Johnson in the fourth quarter valued at about $6,355,000. Fulton Bank N.A. raised its holdings in Johnson & Johnson by 7.8% in the fourth quarter. Fulton Bank N.A. now owns 47,550 shares of the company’s stock worth $6,877,000 after purchasing an additional 3,427 shares in the last quarter. Finally, Innova Wealth Partners bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $416,000. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Bank of America restated a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Guggenheim increased their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Finally, Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $0.72 on Friday, reaching $142.99. 2,889,769 shares of the company’s stock traded hands, compared to its average volume of 7,017,896. The stock has a 50 day moving average price of $150.03 and a 200-day moving average price of $156.04. The firm has a market cap of $344.27 billion, a price-to-earnings ratio of 20.69, a P/E/G ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.66 earnings per share. Equities research analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.47%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.